{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:01:44Z","timestamp":1793142104458,"version":"4.5.0"},"reference-count":149,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2011,4,14]],"date-time":"2011-04-14T00:00:00Z","timestamp":1302739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Zoledronic acid and pamidronate are two potent anticatabolic nitrogen-containing bisphosphonates (BPs) used extensively in diseases with high bone turnover such as multiple myeloma (MM). In this review we focus on their biology and their current and future use in MM, and highlight some of the most common and emerging side effects. Although the primary target cells for BPs are osteoclasts, new insights suggest other cell types of the bone microenvironment as possible targets, including osteoblasts, endothelial cells, immune cells, and cancer cells. Here, we focus on the current guidelines for the use of BPs in MM and address side effects such as renal toxicity, osteonecrosis of the jaw, and low-energy fractures. Finally, we approach the future of BP use in MM in the context of other bone-targeted agents, evaluating ongoing clinical trials addressing alternate dosing and schedules of BP administration in MM patients.<\/jats:p>","DOI":"10.1634\/theoncologist.2010-0225","type":"journal-article","created":{"date-parts":[[2011,4,15]],"date-time":"2011-04-15T01:02:55Z","timestamp":1302829375000},"page":"651-662","source":"Crossref","is-referenced-by-count":65,"title":["The Role of Bisphosphonates in Multiple Myeloma: Mechanisms, Side Effects, and the Future"],"prefix":"10.1093","volume":"16","author":[{"given":"Samantha","family":"Pozzi","sequence":"first","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noopur","family":"Raje","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2011,4,14]]},"reference":[{"key":"2021122303332735100_B1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/bcr414","article-title":"Development of bisphosphonates","volume":"4","author":"Fleisch","year":"2002","journal-title":"Breast Cancer Res"},{"issue":"3 suppl","key":"2021122303332735100_B2","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/cncr.11128","article-title":"Antitumor effects of bisphosphonates","volume":"97","author":"Green","year":"2003","journal-title":"Cancer"},{"issue":"suppl 2","key":"2021122303332735100_B3","doi-asserted-by":"crossref","first-page":"S142","DOI":"10.1007\/s00586-003-0622-z","article-title":"Bisphosphonates in osteoporosis","volume":"12","author":"Fleisch","year":"2003","journal-title":"Eur Spine J"},{"key":"2021122303332735100_B4","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/nrrheum.2009.149","article-title":"Paget disease: When to treat and when not to treat","volume":"5","author":"Singer","year":"2009","journal-title":"Nat Rev Rheumatol"},{"key":"2021122303332735100_B5","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1200\/JCO.1998.16.12.3890","article-title":"Current use of bisphosphonates in oncology. International Bone and Cancer Study Group","volume":"16","author":"Body","year":"1998","journal-title":"J Clin Oncol"},{"issue":"5 suppl","key":"2021122303332735100_B6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.joms.2008.12.006","article-title":"Alternative indications for bisphosphonate therapy","volume":"67","author":"Landesberg","year":"2009","journal-title":"J Oral Maxillofac Surg"},{"key":"2021122303332735100_B7","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/1529-0131(200107)44:7<1496::AID-ART271>3.0.CO;2-5","article-title":"Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis","volume":"44","year":"2001","journal-title":"Arthritis Rheum"},{"key":"2021122303332735100_B8","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11914-010-0003-6","article-title":"Glucocorticoid-induced osteoporosis: Management update","volume":"8","author":"Adler","year":"2010","journal-title":"Curr Osteoporos Rep"},{"key":"2021122303332735100_B9","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.jbspin.2009.10.003","article-title":"Bone loss in patients with HIV infection","volume":"76","author":"Paccou","year":"2009","journal-title":"Joint Bone Spine"},{"key":"2021122303332735100_B10","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/S0140-6736(09)60221-X","article-title":"Multiple myeloma","volume":"374","author":"Raab","year":"2009","journal-title":"Lancet"},{"key":"2021122303332735100_B11","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/annonc\/mdn796","article-title":"The use of bisphosphonates in multiple myeloma: Recommendations of an expert panel on behalf of the European Myeloma Network","volume":"20","author":"Terpos","year":"2009","journal-title":"Ann Oncol"},{"key":"2021122303332735100_B12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/leu.2008.291","article-title":"Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma","volume":"23","author":"Kyle","year":"2009","journal-title":"Leukemia"},{"key":"2021122303332735100_B13","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"2021122303332735100_B14","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.bcmd.2004.01.001","article-title":"Pathogenesis of myeloma bone disease","volume":"32","author":"Roodman","year":"2004","journal-title":"Blood Cells Mol Dis"},{"key":"2021122303332735100_B15","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/leu.2008.336","article-title":"Pathogenesis of myeloma bone disease","volume":"23","author":"Roodman","year":"2009","journal-title":"Leukemia"},{"key":"2021122303332735100_B16","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1056\/NEJMoa030847","article-title":"The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma","volume":"349","author":"Tian","year":"2003","journal-title":"N Engl J Med"},{"key":"2021122303332735100_B17","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.clinthera.2009.05.009","article-title":"Efficacy of clodronate, pamidronate, and zoledronate in reducing morbidity and mortality in cancer patients with bone metastasis: A meta-analysis of randomized clinical trials","volume":"31","author":"Machado","year":"2009","journal-title":"Clin Ther"},{"key":"2021122303332735100_B18","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.2174\/1381612033453640","article-title":"New insights into the molecular mechanisms of action of bisphosphonates","volume":"9","author":"Rogers","year":"2003","journal-title":"Curr Pharm Des"},{"key":"2021122303332735100_B19","doi-asserted-by":"crossref","first-page":"6222s","DOI":"10.1158\/1078-0432.CCR-06-0843","article-title":"Molecular mechanisms of action of bisphosphonates: Current status","volume":"12","author":"Roelofs","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2021122303332735100_B20","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/8756-3282(95)00445-9","article-title":"Bisphosphonates: A review of their pharmacokinetic properties","volume":"18","author":"Lin","year":"1996","journal-title":"Bone"},{"key":"2021122303332735100_B21","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s00228-001-0411-8","article-title":"A pharmacokinetic and pharmacodynamic model for intravenous bisphosphonate (pamidronate) in osteoporosis","volume":"57","author":"Cremers","year":"2002","journal-title":"Eur J Clin Pharmacol"},{"key":"2021122303332735100_B22","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1196\/annals.1402.089","article-title":"Bisphosphonates: An update on mechanisms of action and how these relate to clinical efficacy","volume":"1117","author":"Russell","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"2021122303332735100_B23","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1172\/JCI115539","article-title":"Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure","volume":"88","author":"Sato","year":"1991","journal-title":"J Clin Invest"},{"key":"2021122303332735100_B24","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1124\/mol.105.020776","article-title":"Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis","volume":"69","author":"Thompson","year":"2006","journal-title":"Mol Pharmacol"},{"key":"2021122303332735100_B25","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1476-5381.2009.00160.x","article-title":"Zoledronic acid induces formation of a pro-apoptotic ATP analogue and isopentenyl pyrophosphate in osteoclasts in vivo and in MCF-7 cells in vitro","volume":"157","author":"R\u00e4ikk\u00f6nen","year":"2009","journal-title":"Br J Pharmacol"},{"key":"2021122303332735100_B26","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1359\/jbmr.091009","article-title":"Fluorescent risedronate analogues reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo","volume":"25","author":"Roelofs","year":"2010","journal-title":"J Bone Miner Res"},{"key":"2021122303332735100_B27","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1172\/JCI6800","article-title":"Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin","volume":"104","author":"Plotkin","year":"1999","journal-title":"J Clin Invest"},{"key":"2021122303332735100_B28","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.bone.2006.02.060","article-title":"Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts\/osteocytes with novel analogs","volume":"39","author":"Plotkin","year":"2006","journal-title":"Bone"},{"key":"2021122303332735100_B29","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1359\/jbmr.080617","article-title":"Connexin 43 is required for the anti-apoptotic effect of bisphosphonates on osteocytes and osteoblasts in vivo","volume":"23","author":"Plotkin","year":"2008","journal-title":"J Bone Miner Res"},{"key":"2021122303332735100_B30","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/jcb.21983","article-title":"Inhibition of osteoblast function in vitro by aminobisphosphonates","volume":"106","author":"Orriss","year":"2009","journal-title":"J Cell Biochem"},{"key":"2021122303332735100_B31","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/ajh.21553","article-title":"Bisphosphonates-associated osteonecrosis of the jaw: A long-term follow-up of a series of 35 cases observed by GISL and evaluation of its frequency over time","volume":"84","author":"Pozzi","year":"2009","journal-title":"Am J Hematol"},{"key":"2021122303332735100_B32","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00784-009-0266-4","article-title":"Influence of bisphosphonates on endothelial cells, fibroblasts, and osteogenic cells","volume":"14","author":"Walter","year":"2010","journal-title":"Clin Oral Investig"},{"key":"2021122303332735100_B33","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.archoralbio.2009.06.002","article-title":"Zoledronic acid decreases bone formation without causing osteocyte death in mice","volume":"54","author":"Huja","year":"2009","journal-title":"Arch Oral Biol"},{"key":"2021122303332735100_B34","first-page":"121","article-title":"Clodronate stimulates bone formation as well as inhibits bone resorption and increases bone mineral density in rats fed a low-calcium diet","volume":"50","author":"Horie","year":"2003","journal-title":"J Med Dent Sci"},{"key":"2021122303332735100_B35","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1124\/jpet.102.035295","article-title":"Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid","volume":"302","author":"Wood","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"2021122303332735100_B36","first-page":"6538","article-title":"Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats","volume":"62","author":"Fournier","year":"2002","journal-title":"Cancer Res"},{"key":"2021122303332735100_B37","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1538-7836.2006.02259.x","article-title":"Zoledronate inhibits endothelial cell adhesion, migration and survival through the suppression of multiple, prenylation-dependent signaling pathways","volume":"5","author":"Hasmim","year":"2007","journal-title":"J Thromb Haemost"},{"key":"2021122303332735100_B38","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1158\/1535-7163.MCT-07-0311","article-title":"Zoledronic acid affects over-angiogenic phenotype of endothelial cells in patients with multiple myeloma","volume":"6","author":"Scavelli","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"2021122303332735100_B39","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1359\/jbmr.2003.18.3.482","article-title":"Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: Evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival","volume":"18","author":"Croucher","year":"2003","journal-title":"J Bone Miner Res"},{"key":"2021122303332735100_B40","first-page":"2893","article-title":"Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients","volume":"9","author":"Santini","year":"2003","journal-title":"Clin Cancer Res"},{"key":"2021122303332735100_B41","doi-asserted-by":"crossref","first-page":"4971","DOI":"10.1158\/0008-5472.CAN-05-0264","article-title":"Bisphosphonates and cancer-induced bone disease: Beyond their antiresorptive activity","volume":"65","author":"Cl\u00e9zardin","year":"2005","journal-title":"Cancer Res"},{"issue":"suppl 4","key":"2021122303332735100_B42","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1634\/theoncologist.9-90004-3","article-title":"Bisphosphonates: Preclinical review","volume":"9","author":"Green","year":"2004","journal-title":"The Oncologist"},{"key":"2021122303332735100_B43","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood.V96.2.384","article-title":"Stimulation of \u03b3\u03b4 T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma","volume":"96","author":"Kunzmann","year":"2000","journal-title":"Blood"},{"key":"2021122303332735100_B44","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/sj.leu.2400892","article-title":"In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates","volume":"12","author":"Aparicio","year":"1998","journal-title":"Leukemia"},{"key":"2021122303332735100_B45","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1359\/jbmr.1999.14.12.2048","article-title":"Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment","volume":"14","author":"Derenne","year":"1999","journal-title":"J Bone Miner Res"},{"key":"2021122303332735100_B46","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1046\/j.1365-2141.1997.2713086.x","article-title":"Bisphosphonates induce apoptosis in human myeloma cell lines: A novel anti-tumour activity","volume":"98","author":"Shipman","year":"1997","journal-title":"Br J Haematol"},{"key":"2021122303332735100_B47","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1046\/j.1365-2141.2002.03824.x","article-title":"Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myeloma","volume":"119","author":"Gordon","year":"2002","journal-title":"Br J Haematol"},{"key":"2021122303332735100_B48","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1002\/ijc.21977","article-title":"Selective inhibition of Rab prenylation by a phosphonocarboxylate analogue of risedronate induces apoptosis, but not S-phase arrest, in human myeloma cells","volume":"119","author":"Roelofs","year":"2006","journal-title":"Int J Cancer"},{"key":"2021122303332735100_B49","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1182\/blood-2002-12-3665","article-title":"\u03b3\u03b4 T cells for immune therapy of patients with lymphoid malignancies","volume":"102","author":"Wilhelm","year":"2003","journal-title":"Blood"},{"key":"2021122303332735100_B50","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/sj.leu.2403693","article-title":"Effector \u03b3\u03b4 T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma","volume":"19","author":"Mariani","year":"2005","journal-title":"Leukemia"},{"key":"2021122303332735100_B51","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.exphem.2009.04.008","article-title":"Clinical and immunological evaluation of zoledronate-activated V\u03b39\u03b3\u03b4 T-cell-based immunotherapy for patients with multiple myeloma","volume":"37","author":"Abe","year":"2009","journal-title":"Exp Hematol"},{"key":"2021122303332735100_B52","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.bbrc.2007.01.031","article-title":"\u03b3\u03b4 T cells kill myeloma cells by sensing mevalonate metabolites and ICAM-1 molecules on cell surface","volume":"354","author":"Uchida","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"2021122303332735100_B53","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/ijc.24758","article-title":"The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation","volume":"126","author":"Guenther","year":"2010","journal-title":"Int J Cancer"},{"key":"2021122303332735100_B54","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/j.1600-0609.2005.00427.x","article-title":"The bisphosphonate zoledronic acid inhibits the development of plasmacytoma induced in BALB\/c mice by intraperitoneal injection of pristane","volume":"74","author":"Avcu","year":"2005","journal-title":"Eur J Haematol"},{"key":"2021122303332735100_B55","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/cncr.23783","article-title":"A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma","volume":"113","author":"Musto","year":"2008","journal-title":"Cancer"},{"key":"2021122303332735100_B56","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/0140-6736(92)93075-X","article-title":"Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group","volume":"340","author":"Lahtinen","year":"1992","journal-title":"Lancet"},{"key":"2021122303332735100_B57","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM199602223340802","article-title":"Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group","volume":"334","author":"Berenson","year":"1996","journal-title":"N Engl J Med"},{"key":"2021122303332735100_B58","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1046\/j.1365-2141.1998.00695.x","article-title":"Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: A double-blind placebo-controlled trial. Danish-Swedish co-operative study group","volume":"101","author":"Brincker","year":"1998","journal-title":"Br J Haematol"},{"key":"2021122303332735100_B59","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1046\/j.1365-2141.1998.00567.x","article-title":"A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults","volume":"100","author":"McCloskey","year":"1998","journal-title":"Br J Haematol"},{"key":"2021122303332735100_B60","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/S0140-6736(10)62051-X","article-title":"First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): A randomised controlled trial","volume":"376","author":"Morgan","year":"2010","journal-title":"Lancet"},{"key":"2021122303332735100_B61","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1056\/NEJMoa0806285","article-title":"Endocrine therapy plus zoledronic acid in premenopausal breast cancer","volume":"360","author":"Gnant","year":"2009","journal-title":"N Engl J Med"},{"key":"2021122303332735100_B62","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMoa054494","article-title":"Prevalence of monoclonal gammopathy of undetermined significance","volume":"354","author":"Kyle","year":"2006","journal-title":"N Engl J Med"},{"key":"2021122303332735100_B63","doi-asserted-by":"crossref","first-page":"685","DOI":"10.4065\/84.8.685","article-title":"Disease associations with monoclonal gammopathy of undetermined significance: A population-based study of 17,398 patients","volume":"84","author":"Bida","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"2021122303332735100_B64","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1182\/blood.V90.9.3743","article-title":"Bone resorption in multiple myeloma and in monoclonal gammopathy of undetermined significance: Quantification by urinary pyridinium cross-links of collagen","volume":"90","author":"Pecherstorfer","year":"1997","journal-title":"Blood"},{"key":"2021122303332735100_B65","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1600-0609.1997.tb00932.x","article-title":"Abnormal bone turnover in monoclonal gammopathy of undetermined significance: Analyses of type I collagen telopeptide, osteocalcin, bone-specific alkaline phosphatase and propeptides of type I and type III procollagens","volume":"58","author":"Vejlgaard","year":"1997","journal-title":"Eur J Haematol"},{"key":"2021122303332735100_B66","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1046\/j.1445-5994.2001.00055.x","article-title":"Non-invasive markers of bone turnover and plasma cytokines differ in osteoporotic patients with multiple myeloma and monoclonal gammopathies of undetermined significance","volume":"31","author":"Diamond","year":"2001","journal-title":"Intern Med J"},{"key":"2021122303332735100_B67","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1365-2141.2006.06217.x","article-title":"Lumbar bone mineral density as the major factor determining increased prevalence of vertebral fractures in monoclonal gammopathy of undetermined significance","volume":"134","author":"Pepe","year":"2006","journal-title":"Br J Haematol"},{"key":"2021122303332735100_B68","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.1182\/blood.V87.11.4762.bloodjournal87114762","article-title":"Quantifiable excess of bone resorption in monoclonal gammopathy is an early symptom of malignancy: A prospective study of 87 bone biopsies","volume":"87","author":"Bataille","year":"1996","journal-title":"Blood"},{"key":"2021122303332735100_B69","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1359\/jbmr.0301212","article-title":"Fracture risk in monoclonal gammopathy of undetermined significance","volume":"19","author":"Melton","year":"2004","journal-title":"J Bone Miner Res"},{"key":"2021122303332735100_B70","doi-asserted-by":"crossref","first-page":"6289","DOI":"10.1158\/1078-0432.CCR-08-0666","article-title":"Zoledronic acid markedly improves bone mineral density for patients with monoclonal gammopathy of undetermined significance and bone loss","volume":"14","author":"Berenson","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2021122303332735100_B71","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1365-2257.2006.00860.x","article-title":"Is there a case for the early use of bisphosphonates in smouldering myeloma and MGUS? (Bisphosphonates in SMM & MGUS)","volume":"29","author":"Sanders","year":"2007","journal-title":"Int J Lab Hematol"},{"key":"2021122303332735100_B72","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1200\/JCO.2007.12.1269","article-title":"American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma","volume":"25","author":"Kyle","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122303332735100_B73","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International Myeloma Working Group","volume":"121","year":"2003","journal-title":"Br J Haematol"},{"key":"2021122303332735100_B74","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"N Engl J Med"},{"key":"2021122303332735100_B75","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1046\/j.1365-2141.2002.03549.x","article-title":"Pamidronate induces bone formation in patients with smouldering or indolent myeloma, with no significant anti-tumour effect","volume":"118","author":"Mart\u00edn","year":"2002","journal-title":"Br J Haematol"},{"key":"2021122303332735100_B76","first-page":"1720","article-title":"The effect of zoledronic acid on serum osteoprotegerin in early stage multiple myeloma","volume":"91","author":"Martini","year":"2006","journal-title":"Haematologica"},{"key":"2021122303332735100_B77","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1046\/j.1365-2141.2001.02851.x","article-title":"Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma","volume":"113","author":"McCloskey","year":"2001","journal-title":"Br J Haematol"},{"key":"2021122303332735100_B78","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1200\/JCO.1998.16.2.593","article-title":"Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group","volume":"16","author":"Berenson","year":"1998","journal-title":"J Clin Oncol"},{"key":"2021122303332735100_B79","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO;2-0","article-title":"Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases","volume":"91","author":"Berenson","year":"2001","journal-title":"Cancer"},{"key":"2021122303332735100_B80","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer J"},{"key":"2021122303332735100_B81","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1200\/JCO.2002.02.032","article-title":"Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma","volume":"20","author":"Menssen","year":"2002","journal-title":"J Clin Oncol"},{"key":"2021122303332735100_B82","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1034\/j.1600-0609.2003.02823.x","article-title":"Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma","volume":"70","author":"Terpos","year":"2003","journal-title":"Eur J Haematol"},{"key":"2021122303332735100_B83","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1046\/j.0902-4441.2003.132_1.x","article-title":"Is ibandronate effective in multiple myeloma?","volume":"71","author":"Body","year":"2003","journal-title":"Eur J Haematol"},{"key":"2021122303332735100_B84","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.pain.2004.07.011","article-title":"Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer","volume":"111","author":"Body","year":"2004","journal-title":"Pain"},{"key":"2021122303332735100_B85","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/annonc\/mdg367","article-title":"Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases","volume":"14","author":"Body","year":"2003","journal-title":"Ann Oncol"},{"key":"2021122303332735100_B86","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.4065\/81.8.1047","article-title":"Mayo Clinic consensus statement for the use of bisphosphonates in multiple myeloma","volume":"81","author":"Lacy","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"2021122303332735100_B87","doi-asserted-by":"crossref","first-page":"516","DOI":"10.4065\/82.4.516","article-title":"Use of bisphosphonates in multiple myeloma: IMWG response to Mayo Clinic consensus statement","volume":"82","author":"Durie","year":"2007","journal-title":"Mayo Clin Proc"},{"key":"2021122303332735100_B88","doi-asserted-by":"crossref","first-page":"908","DOI":"10.6004\/jnccn.2009.0061","article-title":"NCCN clinical practice guidelines in oncology: Multiple myeloma","volume":"7","author":"Anderson","year":"2009","journal-title":"J Natl Compr Canc Netw"},{"issue":"suppl 1","key":"2021122303332735100_B89","doi-asserted-by":"crossref","first-page":"i45","DOI":"10.1093\/annonc\/mdi818","article-title":"ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of multiple myeloma","volume":"16","author":"Harrouseau","year":"2005","journal-title":"Ann Oncol"},{"key":"2021122303332735100_B90","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1182\/blood-2006-05-022962","article-title":"Maintenance therapy with thalidomide improves survival in patients with multiple myeloma","volume":"108","author":"Attal","year":"2006","journal-title":"Blood"},{"key":"2021122303332735100_B91","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/BF02390835","article-title":"Pamidronate increases markers of bone formation in patients with multiple myeloma in plateau phase under interferon-alpha treatment","volume":"68","author":"Terpos","year":"2001","journal-title":"Calcif Tissue Int"},{"key":"2021122303332735100_B92","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1177\/1078155207080806","article-title":"Significance and impact of bisphosphonate-induced acute phase responses","volume":"13","author":"Olson","year":"2007","journal-title":"J Oncol Pharm Pract"},{"key":"2021122303332735100_B93","doi-asserted-by":"crossref","first-page":"96","DOI":"10.14310\/horm.2002.1226","article-title":"Bisphosphonate-associated adverse events","volume":"8","author":"Papapetrou","year":"2009","journal-title":"Hormones (Athens)"},{"issue":"suppl 4","key":"2021122303332735100_B94","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1634\/theoncologist.9-90004-28","article-title":"Safety of intravenous and oral bisphosphonates and compliance with dosing regimens","volume":"9","author":"Conte","year":"2004","journal-title":"The Oncologist"},{"key":"2021122303332735100_B95","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"2021122303332735100_B96","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/cncr.20308","article-title":"Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: A randomized, phase III, double-blind, placebo-controlled trial","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"issue":"suppl 1","key":"2021122303332735100_B97","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1634\/theoncologist.10-90001-3","article-title":"Preclinical perspectives on bisphosphonate renal safety","volume":"10","author":"Body","year":"2005","journal-title":"The Oncologist"},{"key":"2021122303332735100_B98","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4103\/0973-1482.63570","article-title":"Renal toxicity in patients with multiple myeloma receiving zoledronic acid vs. ibandronate: A retrospective medical records review","volume":"6","author":"Weide","year":"2010","journal-title":"J Cancer Res Ther"},{"issue":"suppl 1","key":"2021122303332735100_B99","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1634\/theoncologist.10-90001-14","article-title":"Renal safety of ibandronate","volume":"10","author":"Jackson","year":"2005","journal-title":"The Oncologist"},{"key":"2021122303332735100_B100","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1159\/000094676","article-title":"Ibandronate for the treatment of hypercalcemia or nephrocalcinosis in patients with multiple myeloma and acute renal failure: Case reports","volume":"116","author":"Henrich","year":"2006","journal-title":"Acta Haematol"},{"key":"2021122303332735100_B101","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.tox.2003.11.013","article-title":"Comparative renal effects of two intravenously administered bisphosphonates","volume":"196","author":"Pfister","year":"2004","journal-title":"Toxicology"},{"key":"2021122303332735100_B102","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1046\/j.1523-1755.2003.00071.x","article-title":"Toxic acute tubular necrosis following treatment with zoledronate (Zometa)","volume":"64","author":"Markowitz","year":"2003","journal-title":"Kidney Int"},{"key":"2021122303332735100_B103","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1046\/j.1365-2141.2002.03826.x","article-title":"Nephrotic proteinuria associated with high-dose pamidronate in multiple myeloma","volume":"119","author":"Desikan","year":"2002","journal-title":"Br J Haematol"},{"key":"2021122303332735100_B104","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/ndt\/gfg567","article-title":"Collapsing glomerulopathy induced by long-term treatment with standard-dose pamidronate in a myeloma patient","volume":"19","author":"Kunin","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"2021122303332735100_B105","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM200310233491721","article-title":"Renal failure with the use of zoledronic acid","volume":"349","author":"Chang","year":"2003","journal-title":"N Engl J Med"},{"key":"2021122303332735100_B106","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1345\/aph.1E589","article-title":"Zoledronic acid and renal toxicity: Data from French adverse effect reporting database","volume":"39","author":"Munier","year":"2005","journal-title":"Ann Pharmacother"},{"key":"2021122303332735100_B107","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic","volume":"61","author":"Marx","year":"2003","journal-title":"J Oral Maxillofac Surg"},{"key":"2021122303332735100_B108","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.joms.2004.02.004","article-title":"Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases","volume":"62","author":"Ruggiero","year":"2004","journal-title":"J Oral Maxillofac Surg"},{"key":"2021122303332735100_B109","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: Report of a task force of the American Society for Bone and Mineral Research","volume":"22","author":"Khosla","year":"2007","journal-title":"J Bone Miner Res"},{"key":"2021122303332735100_B110","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.joms.2006.11.003","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws","volume":"65","year":"2007","journal-title":"J Oral Maxillofac Surg"},{"key":"2021122303332735100_B111","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1747-4477.2009.00213.x","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw - 2009 update","volume":"35","author":"Ruggiero","year":"2009","journal-title":"Aust Endod J"},{"key":"2021122303332735100_B112","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1016\/j.joms.2009.07.097","article-title":"American Association of Oral and Maxillofacial Surgeons position paper: Bisphosphonate-related osteonecrosis of the jaws-2009 update: The need to refine the BRONJ definition","volume":"67","author":"Colella","year":"2009","journal-title":"J Oral Maxillofac Surg"},{"key":"2021122303332735100_B113","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/j.1601-0825.2009.01568.x","article-title":"Bisphosphonate-related osteonecrosis: Genetic and acquired risk factors","volume":"15","author":"Sarasquete","year":"2009","journal-title":"Oral Dis"},{"issue":"5 suppl","key":"2021122303332735100_B114","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.joms.2009.01.007","article-title":"The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: So many hypotheses, so few data","volume":"67","author":"Allen","year":"2009","journal-title":"J Oral Maxillofac Surg"},{"key":"2021122303332735100_B115","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1158\/1078-0432.CCR-07-1430","article-title":"Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw","volume":"14","author":"Raje","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2021122303332735100_B116","first-page":"36","article-title":"New oncology drugs and osteonecrosis of the jaw (ONJ)","volume":"89","author":"Migliorati","year":"2009","journal-title":"J Tenn Dent Assoc"},{"key":"2021122303332735100_B117","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00774-009-0128-9","article-title":"Zoledronic acid delays wound healing of the tooth extraction socket, inhibits oral epithelial cell migration, and promotes proliferation and adhesion to hydroxyapatite of oral bacteria, without causing osteonecrosis of the jaw, in mice","volume":"28","author":"Kobayashi","year":"2010","journal-title":"J Bone Miner Metab"},{"key":"2021122303332735100_B118","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/j.1365-2141.2008.07504.x","article-title":"Effect of zoledronic acid on oral fibroblasts and epithelial cells: A potential mechanism of bisphosphonate-associated osteonecrosis","volume":"144","author":"Scheper","year":"2009","journal-title":"Br J Haematol"},{"key":"2021122303332735100_B119","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.bjoms.2009.08.030","article-title":"Osteonecrosis of the jaws induced by anti-RANK ligand therapy","volume":"48","author":"Taylor","year":"2010","journal-title":"Br J Oral Maxillofac Surg"},{"key":"2021122303332735100_B120","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.joms.2009.10.010","article-title":"Osteonecrosis of the jaw in a patient on denosumab","volume":"68","author":"Aghaloo","year":"2010","journal-title":"J Oral Maxillofac Surg"},{"key":"2021122303332735100_B121","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.bone.2006.11.023","article-title":"Jaw osteonecrosis related to bisphosphonate therapy: A severe secondary disorder","volume":"40","author":"Dannemann","year":"2007","journal-title":"Bone"},{"key":"2021122303332735100_B122","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1080\/10428190802483778","article-title":"Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates","volume":"49","author":"Montefusco","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"2021122303332735100_B123","doi-asserted-by":"crossref","first-page":"5356","DOI":"10.1200\/JCO.2009.21.9584","article-title":"Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw","volume":"27","author":"Vahtsevanos","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122303332735100_B124","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/annonc\/mdn554","article-title":"Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid","volume":"20","author":"Dimopoulos","year":"2009","journal-title":"Ann Oncol"},{"issue":"15 suppl","key":"2021122303332735100_B125","doi-asserted-by":"crossref","first-page":"20526","DOI":"10.1200\/jco.2008.26.15_suppl.20526","article-title":"Outcomes of bisphosphonate-related osteonecrosis of the jaw\u2014importance of staging and management guidelines: A large single institutional update","volume":"26","author":"Mehrotra","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122303332735100_B126","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.joms.2005.07.010","article-title":"Bisphosphonate-induced exposed bone (osteonecrosis\/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment","volume":"63","author":"Marx","year":"2005","journal-title":"J Oral Maxillofac Surg"},{"key":"2021122303332735100_B127","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1056\/NEJMc0707493","article-title":"Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate","volume":"358","author":"Lenart","year":"2008","journal-title":"N Engl J Med"},{"key":"2021122303332735100_B128","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1365-2265.2009.03581.x","article-title":"Unusual mid-shaft fractures during long-term bisphosphonate therapy","volume":"72","author":"Odvina","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2021122303332735100_B129","doi-asserted-by":"crossref","first-page":"775","DOI":"10.2165\/00002018-200932090-00002","article-title":"Low-energy femoral fractures associated with the long-term use of bisphosphonates: A case series from a Swiss university hospital","volume":"32","author":"Ing-Lorenzini","year":"2009","journal-title":"Drug Saf"},{"key":"2021122303332735100_B130","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/BOT.0b013e318172841c","article-title":"Low-energy femoral shaft fractures associated with alendronate use","volume":"22","author":"Neviaser","year":"2008","journal-title":"J Orthop Trauma"},{"key":"2021122303332735100_B131","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.2106\/JBJS.H.01774","article-title":"Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy","volume":"91","author":"Capeci","year":"2009","journal-title":"J Bone Joint Surg Am"},{"key":"2021122303332735100_B132","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00223-009-9263-5","article-title":"Bone turnover in bone biopsies of patients with low-energy cortical fractures receiving bisphosphonates: A case series","volume":"85","author":"Armamento-Villareal","year":"2009","journal-title":"Calcif Tissue Int"},{"key":"2021122303332735100_B133","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1359\/jbmr.081247","article-title":"Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: A register-based national cohort study","volume":"24","author":"Abrahamsen","year":"2009","journal-title":"J Bone Miner Res"},{"key":"2021122303332735100_B134","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMoa1001086","article-title":"Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur","volume":"362","author":"Black","year":"2010","journal-title":"N Engl J Med"},{"key":"2021122303332735100_B135","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s11420-008-9077-4","article-title":"Case report of spontaneous, nonspinal fractures in a multiple myeloma patient on long-term pamidronate and zoledronic acid","volume":"4","author":"Wernecke","year":"2008","journal-title":"HSS J"},{"key":"2021122303332735100_B136","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.joms.2008.11.005","article-title":"Recurrent low-energy femoral shaft fractures and osteonecrosis of the jaw in a case of multiple myeloma treated with bisphosphonates","volume":"67","author":"Grasko","year":"2009","journal-title":"J Oral Maxillofac Surg"},{"key":"2021122303332735100_B137","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1007\/s11999-009-1192-0","article-title":"Case reports: Subtrochanteric femoral stress fractures after prolonged alendronate therapy","volume":"468","author":"Cermak","year":"2010","journal-title":"Clin Orthop Relat Res"},{"key":"2021122303332735100_B138","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1359\/jbmr.2000.15.4.613","article-title":"Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib","volume":"15","author":"Mashiba","year":"2000","journal-title":"J Bone Miner Res"},{"key":"2021122303332735100_B139","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S8756-3282(01)00414-8","article-title":"Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles","volume":"28","author":"Mashiba","year":"2001","journal-title":"Bone"},{"key":"2021122303332735100_B140","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S8756-3282(00)00284-2","article-title":"Does suppression of bone turnover impair mechanical properties by allowing microdamage accumulation?","volume":"27","author":"Hirano","year":"2000","journal-title":"Bone"},{"key":"2021122303332735100_B141","doi-asserted-by":"crossref","first-page":"5829","DOI":"10.1158\/1078-0432.CCR-09-0426","article-title":"High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties","volume":"15","author":"Pozzi","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2021122303332735100_B142","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/blood.V116.21.2971.2971","article-title":"Bone marker directed dosing of zoledronic acid for the prevention of skeletal complications in patients with multiple myeloma: Interim analysis results of the Z-MARK study [abstract 2971]","volume":"116","author":"Raje","year":"2010","journal-title":"Blood"},{"issue":"15 suppl","key":"2021122303332735100_B143","doi-asserted-by":"crossref","first-page":"8140","DOI":"10.1200\/jco.2010.28.15_suppl.8140","article-title":"Bone marker assessment as a guide to chronic use of aminobisphosphonates in multiple myeloma","volume":"28","author":"Raje","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122303332735100_B144","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1182\/blood.V110.11.533.533","article-title":"Randomised study on prophylactic pamidronate 30 mg versus 90 mg in multiple myeloma","volume":"110","author":"Gimsing","year":"2007","journal-title":"Blood"},{"key":"2021122303332735100_B145","year":"2010"},{"key":"2021122303332735100_B146","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"key":"2021122303332735100_B147","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMoa0809003","article-title":"Denosumab in men receiving androgen-deprivation therapy for prostate cancer","volume":"361","author":"Smith","year":"2009","journal-title":"N Engl J Med"},{"key":"2021122303332735100_B148","doi-asserted-by":"crossref","first-page":"5124","DOI":"10.1073\/pnas.0911929107","article-title":"Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease","volume":"107","author":"Vallet","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2021122303332735100_B149","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1182\/blood-2007-05-093294","article-title":"MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts","volume":"110","author":"Vallet","year":"2007","journal-title":"Blood"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2010-0225","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2010-0225","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/16\/5\/651\/41853536\/oncolo_16_5_651.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/16\/5\/651\/41853536\/oncolo_16_5_651.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T06:05:26Z","timestamp":1640239526000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/16\/5\/651\/6400802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,14]]},"references-count":149,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2011,4,14]]},"published-print":{"date-parts":[[2011,5,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2010-0225","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2011,5,1]]},"published":{"date-parts":[[2011,4,14]]}}}